Keto diet plus breast cancer drug shows promise in small study
NCT ID NCT03962647
First seen May 06, 2026
Summary
This early-phase study tested whether a 2-week very low-carbohydrate (ketogenic) diet combined with the drug letrozole is feasible and tolerable for people with early-stage estrogen receptor-positive (ER+) breast cancer. 31 postmenopausal women participated before surgery. The goal was to see if the diet could be followed and if it affected cancer cell growth and insulin signaling.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESTROGEN RECEPTOR POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.